Annual report pursuant to Section 13 and 15(d)

Document And Entity Information

v3.23.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 17, 2023
Jun. 30, 2022
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 001-35076    
Entity Registrant Name NAVIDEA BIOPHARMACEUTICALS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 31-1080091    
Entity Address, Address Line One 4995 Bradenton Avenue, Suite 240    
Entity Address, City or Town Dublin    
Entity Address, State or Province OH    
Entity Address, Postal Zip Code 43017-3552    
City Area Code 614    
Local Phone Number 793-7500    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 14,273,755
Entity Common Stock, Shares Outstanding (in shares)   32,851,252  
Auditor Firm ID 688    
Auditor Name Marcum LLP    
Auditor Location Hartford, CT    
Entity Central Index Key 0000810509    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag false    
Common Stock [Member]      
Document Information [Line Items]      
Title of 12(b) Security Common Stock, par value $.001 per share    
Trading Symbol NAVB    
Security Exchange Name NYSEAMER    
Preferred Stock Purchase Rights [Member]      
Document Information [Line Items]      
Title of 12(b) Security Preferred Stock Purchase Rights